(Q38224958)

31 August 2017

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? (English)

1 reference

31 August 2017

0 references

1 reference

1 reference

1

1 reference

31 August 2017

4

Giancarlo Logroscino

1 reference

31 August 2017

Bruno P Imbimbo

3

1 reference

ORCID Public Data File 2021

Vincenzo Solfrizzi

series ordinal

2

object named as

Vincenzo Solfrizzi

1 reference

PubMed ID

24981190

31 August 2017

language of work or name

English

0 references

publication date

30 June 2014

1 reference

Expert Opinion on Biological Therapy

31 August 2017

1 reference

31 August 2017

14

1 reference

31 August 2017

10

1 reference

31 August 2017

1465-1476

1 reference

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

The cell biology of Alzheimer's disease: uncovering the secrets of secretases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Preclinical Alzheimer disease-the challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Brain injury biomarkers are not dependent on β-amyloid in normal elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Immunotherapy for Alzheimer's disease: hoops and hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Antiamyloid therapy for Alzheimer's disease--are we on the right road?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

The A4 study: stopping AD before symptoms begin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Testing the right target and right drug at the right stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Advances in the prevention of Alzheimer's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Gantenerumab for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Regulatory innovation and drug development for early-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

A specific amyloid-beta protein assembly in the brain impairs memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Deciphering the mechanism underlying late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Antioxidant approaches for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Vascular risk factors: a ticking time bomb to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

Autoreactive-Aβ antibodies promote APP β-secretase processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.935332

10.1517/14712598.2014.935332

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24981190